Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$15.74 -3.0%	$14.14	$9.57 ▼ $30.41	$2.17B	0.96	1.53 million shs	1.22 million shs
KURA Kura Oncology	$6.44 -3.3%	$6.13	$5.41 ▼ $23.48	$557.54M	0.4	1.23 million shs	1.12 million shs
NAMS NewAmsterdam Pharma	$20.21 -3.9%	$18.09	$14.06 ▼ $27.29	$2.27B	-0.03	874,393 shs	497,787 shs
RXRX Recursion Pharmaceuticals	$4.92 -4.8%	$4.87	$3.79 ▼ $12.36	$2.00B	0.84	14.94 million shs	37.37 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-3.11%	-1.46%	+6.15%	+5.60%	-37.06%
KURA Kura Oncology	-3.76%	+1.37%	+14.83%	-6.72%	-69.28%
NAMS NewAmsterdam Pharma	+2.59%	+7.79%	+12.16%	-10.01%	+6.21%
RXRX Recursion Pharmaceuticals	-4.26%	+13.13%	+14.63%	-18.58%	-44.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.6049 of 5 stars	3.4	1.0	3.4	2.6	2.5	0.0
KURA Kura Oncology	4.45 of 5 stars	4.5	1.0	4.7	3.9	0.8	0.6
NAMS NewAmsterdam Pharma	2.9774 of 5 stars	3.5	2.0	0.0	2.5	5.0	0.0
RXRX Recursion Pharmaceuticals	1.9294 of 5 stars	3.2	1.0	0.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	177.73% Upside
KURA Kura Oncology	2.93	Moderate Buy	$24.50	280.43% Upside
NAMS NewAmsterdam Pharma	3.00	Buy	$43.00	112.77% Upside
RXRX Recursion Pharmaceuticals	2.33	Hold	$7.60	54.47% Upside

Current Analyst Ratings Breakdown

Latest KURA, ARWR, NAMS, and RXRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00
6/10/2025	NAMS NewAmsterdam Pharma	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$44.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
6/4/2025	NAMS NewAmsterdam Pharma	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$42.00
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/8/2025	NAMS NewAmsterdam Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$42.00 ➝ $40.00
5/6/2025	RXRX Recursion Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $8.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00

(Data available from 6/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$545.21M	3.99	N/A	N/A	$1.54 per share	10.22
KURA Kura Oncology	$67.99M	8.20	N/A	N/A	$5.35 per share	1.20
NAMS NewAmsterdam Pharma	$47.14M	48.13	N/A	N/A	$3.50 per share	5.77
RXRX Recursion Pharmaceuticals	$59.82M	33.44	N/A	N/A	$1.98 per share	2.48

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	N/A	N/A	-236.60%	-64.09%	8/6/2025 (Estimated)
KURA Kura Oncology	-$152.63M	-$2.10	N/A	N/A	N/A	N/A	-44.09%	-39.57%	8/6/2025 (Estimated)
NAMS NewAmsterdam Pharma	-$176.94M	-$1.88	N/A	N/A	N/A	N/A	N/A	N/A	8/6/2025 (Estimated)
RXRX Recursion Pharmaceuticals	-$328.07M	-$1.77	N/A	N/A	N/A	-579.52%	-76.56%	-55.68%	8/6/2025 (Estimated)

Latest KURA, ARWR, NAMS, and RXRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/8/2025	Q1 2025	NAMS NewAmsterdam Pharma	-$0.45	-$0.49	-$0.04	-$0.34	$1.46 million	$2.98 million
5/5/2025	Q1 2025	RXRX Recursion Pharmaceuticals	-$0.44	-$0.50	-$0.06	-$0.50	$18.12 million	$14.75 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
NAMS NewAmsterdam Pharma	N/A	N/A	N/A	N/A	N/A
RXRX Recursion Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	7.27	6.09	6.09
KURA Kura Oncology	0.02	11.47	11.47
NAMS NewAmsterdam Pharma	N/A	10.61	10.61
RXRX Recursion Pharmaceuticals	0.04	4.35	4.35

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
KURA Kura Oncology	N/A
NAMS NewAmsterdam Pharma	89.89%
RXRX Recursion Pharmaceuticals	89.06%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
KURA Kura Oncology	6.40%
NAMS NewAmsterdam Pharma	20.84%
RXRX Recursion Pharmaceuticals	8.43%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	120.68 million	Optionable
KURA Kura Oncology	130	86.58 million	73.49 million	Optionable
NAMS NewAmsterdam Pharma	4	112.27 million	74.37 million	Optionable
RXRX Recursion Pharmaceuticals	400	406.50 million	329.18 million	Optionable

KURA, ARWR, NAMS, and RXRX Headlines

Recent News About These Companies

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading Down 2.2% - Here's Why

June 13 at 2:22 PM | marketbeat.com

Leerink Partnrs Has Positive Estimate for RXRX Q2 Earnings

June 13 at 5:50 AM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 2.4% - Should You Sell?

June 12 at 3:25 PM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4% Higher - Should You Buy?

June 11 at 1:57 PM | marketbeat.com

Insmed surges on lung drug data; Recursion cuts staff

June 11 at 10:56 AM | biopharmadive.com

AI-Focused Recursion Pharmaceuticals Stock Jumped 31% Last Week; Here's Why

June 11 at 2:45 AM | talkmarkets.com

Recursion to lay off 20% of workforce amid biotech funding woes

June 11 at 2:06 AM | msn.com

Recursion: Lack Of Near-Term Catalysts Leaves The Stock Vulnerable

June 11 at 2:06 AM | seekingalpha.com

Recursion lays off 20% of staff in wake of pipeline cutbacks

June 10 at 8:55 PM | fiercebiotech.com

Recursion Pharmaceuticals Stock Is Up 10% Today: What's Happening?

June 10 at 8:55 PM | benzinga.com

Recursion Pharmaceuticals: Recent Readouts Disappointing, Future Readouts Risky

June 10 at 8:55 PM | seekingalpha.com

Recursion Pharma to reduce workforce by 20%

June 10 at 8:55 PM | msn.com

Recursion Pharmaceuticals (RXRX) Jumps 31% On Next-Gen AI

June 10 at 8:55 PM | msn.com

Why Recursion Pharmaceuticals Was Bouncing Higher on Tuesday

June 10 at 6:03 PM | fool.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Trading 4.9% Higher - Should You Buy?

June 10 at 2:15 PM | marketbeat.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Sees Large Volume Increase - Here's What Happened

June 10 at 11:57 AM | marketbeat.com

Recursion to lay off 20% of workforce, narrows focus amid biotech downturn

June 10 at 6:14 AM | reuters.com

Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Up - Should You Buy?

June 9, 2025 | marketbeat.com

California State Teachers Retirement System Grows Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

June 9, 2025 | marketbeat.com

Why Recursion Pharmaceuticals (RXRX) Soared On Friday

June 7, 2025 | insidermonkey.com

Recursion Pharmaceuticals shares surge on AI model release

June 7, 2025 | investing.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KURA, ARWR, NAMS, and RXRX Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$15.74 -0.48 (-2.96%)

Closing price 04:00 PM Eastern

Extended Trading

$15.74 0.00 (0.00%)

As of 04:21 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Kura Oncology NASDAQ:KURA

$6.44 -0.22 (-3.30%)

Closing price 04:00 PM Eastern

Extended Trading

$6.49 +0.05 (+0.76%)

As of 04:29 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

NewAmsterdam Pharma NASDAQ:NAMS

$20.21 -0.82 (-3.90%)

Closing price 04:00 PM Eastern

Extended Trading

$20.23 +0.02 (+0.10%)

As of 04:44 PM Eastern

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.

Recursion Pharmaceuticals NASDAQ:RXRX

$4.92 -0.25 (-4.84%)

Closing price 04:00 PM Eastern

Extended Trading

$4.93 +0.01 (+0.20%)

As of 04:44 PM Eastern

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time